Management of Psychiatric Symptoms in Dementia

Zhao Q.-F. Tan L. Wang H.-F. et al.

The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis.

J Affect Disord. 190: 264-271Leung D.K.Y. Chan W.C. Spector A. et al.

Prevalence of depression, anxiety, and apathy symptoms across dementia stages: A systematic review and meta-analysis.

Int J Geriatr Psychiatry. 36: 1330-1344Eikelboom W.S. van den Berg E. Singleton E.H. et al.

Neuropsychiatric and cognitive symptoms across the Alzheimer disease clinical spectrum: cross-sectional and longitudinal associations.

Neurology. 97: e1276-e1287Ismail Z. Gatchel J. Bateman D.R. et al.

Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria.

Int Psychogeriatr. 30: 185-196Bateman D.R. Gill S. Hu S. et al.

Agitation and impulsivity in mid and late life as possible risk markers for incident dementia.

Alzheimers Dement (N Y). 6: e12016

Managing behavioral and psychological symptoms of dementia.

Psychiatr Clin North Am. 41: 127-139Peters M.E. Schwartz S. Han D. et al.

Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study.

Am J Psychiatry. 172: 460-465Toot S. Swinson T. Devine M. et al.

Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis.

Int Psychogeriatr. 29: 195-208Matsuoka T. Manabe T. Akatsu H. et al.

Factors influencing hospital admission among patients with autopsy-confirmed dementia.

Psychogeriatrics. 19: 255-263Liu S. Liu J. Wang X.-D. et al.

Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer’s disease.

Int Psychogeriatr. 30: 1131-1138Angeles R.C. Berge L.I. Gedde M.H. et al.

Which factors increase informal care hours and societal costs among caregivers of people with dementia? A systematic review of Resource Utilization in Dementia (RUD).

Health Econ Rev. 11: 37Burley C.V. Livingston G. Knapp M.R.J. et al.

Time to invest in prevention and better care of behaviors and psychological symptoms associated with dementia.

Int Psychogeriatr. 31: 1-6van der Linde R.M. Stephan B.C.M. Dening T. et al.

Instruments to measure behavioural and psychological symptoms of dementia.

Int J Methods Psychiatr Res. 23: 69-98

The neuropsychiatric inventory: development and applications.

J Geriatr Psychiatry Neurol. 33: 73-84Reisberg B. Monteiro I. Torossian C. et al.

The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review.

Dement Geriatr Cogn Disord. 38: 89-146

Common sense: addressed to geriatric psychiatrists on the subject of behavioral and psychological symptoms of dementia.

Am J Geriatr Psychiatry. 23: 1209-1213Seritan A.L. Rienas C. Duong T. et al.

Ages at onset of anxiety and depressive disorders in parkinson’s disease.

J Neuropsychiatry Clin Neurosci. 31: 346-352Rascovsky K. Hodges J.R. Knopman D. et al.

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

Brain. 134: 2456-2477Kales H.C. Gitlin L.N. Lyketsos C.G.

Detroit expert panel on assessment and management of neuropsychiatric symptoms of dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel.

J Am Geriatr Soc. 62: 762-769Lichtwarck B. Selbaek G. Kirkevold Ø. et al.

Targeted interdisciplinary model for evaluation and treatment of neuropsychiatric symptoms: A cluster randomized controlled trial.

Am J Geriatr Psychiatry. 26: 25-38Hsu T.-J. Tsai H.-T. Hwang A.-C. et al.

Predictors of non-pharmacological intervention effect on cognitive function and behavioral and psychological symptoms of older people with dementia.

Geriatr Gerontol Int. 17: 28-35Vasudev A. Shariff S.Z. Liu K. et al.

Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004-2013.

Am J Geriatr Psychiatry. 23: 1259-1269Campbell N. Ayub A. Boustani M.A. et al.

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: a meta-analysis.

Clin Interv Aging. 3: 719-728Kishi T. Matsunaga S. Oya K. et al.

Memantine for Alzheimer’s disease: an updated systematic review and meta-analysis.

J Alzheimers Dis. 60: 401-425Tsoi K.K.F. Chan J.Y.C. Leung N.W.Y. et al.

Combination therapy showed limited superiority over monotherapy for Alzheimer disease: a meta-analysis of 14 randomized trials.

J Am Med Dir Assoc. 17: 863.e1-863.e8Brenowitz W.D. Zeki Al Hazzouri A. Vittinghoff E. et al.

Depressive symptoms imputed across the life course are associated with cognitive impairment and cognitive decline.

J Alzheimers Dis. 83: 1379-1389Ly M. Karim H.T. Becker J.T. et al.

Late-life depression and increased risk of dementia: a longitudinal cohort study.

Transl Psychiatry. 11: 147Lee A.T.C. Fung A.W.T. Richards M. et al.

Risk of incident dementia varies with different onset and courses of depression.

J Affect Disord. 282: 915-920Grinberg L.T. Rüb U. Ferretti R.E.L. et al.

The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer’s disease. A precocious onset?.

Neuropathol Appl Neurobiol. 35: 406-416Robinson A.C. Roncaroli F. Davidson Y.S. et al.

Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer’s disease pathology at death.

Int J Geriatr Psychiatry. 36: 713-721Kazmi H. Walker Z. Booij J. et al.

Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson’s disease: a cross-sectional study.

J Neurol Neurosurg Psychiatr. 92: 158-164Tay K.-W. Subramaniam P. Oei T.P.

Cognitive behavioural therapy can be effective in treating anxiety and depression in persons with dementia: a systematic review.

Psychogeriatrics. 19: 264-275Orgeta V. Qazi A. Spector A.E. et al.

Psychological treatments for depression and anxiety in dementia and mild cognitive impairment.

Cochrane Database Syst Rev. : CD009125Wang F.L. Tang Q.Y. Zhang L.L. et al.

Effects of Mindfulness-based Interventions on Dementia Patients: a meta-analysis.

West J Nurs Res. 42: 1163-1173Baruch N. Burgess J. Pillai M. et al.

Treatment for depression comorbid with dementia.

Evid Based Ment Health. 22: 167-171Watt J.A. Goodarzi Z. Veroniki A.A. et al.

Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis.

BMJ. 372: n532Kolberg E. Hjetland G.J. Thun E. et al.

The effects of bright light treatment on affective symptoms in people with dementia: a 24-week cluster randomized controlled trial.

BMC Psychiatry. 21: 377Orgeta V. Tabet N. Nilforooshan R. et al.

Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis.

J Alzheimers Dis. 58: 725-733Dudas R. Malouf R. McCleery J. et al.

Antidepressants for treating depression in dementia.

Cochrane Database Syst Rev. 8: CD003944Hsu T.-W. Stubbs B. Liang C.-S. et al.

Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: A systematic review and meta-analysis.

Ageing Res Rev. 69: 101362Lebert F. Stekke W. Hasenbroekx C. et al.

Frontotemporal dementia: a randomised, controlled trial with trazodone.

Dement Geriatr Cogn Disord. 17: 355-359Sommerlad A. Werbeloff N. Perera G. et al.

Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data.

Int J Geriatr Psychiatry. 25https://doi.org/10.1002/gps.5625Zuidersma M. Chua K.-C. Hellier J. et al.HTA-SADD Investigator Group

Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial.

Am J Geriatr Psychiatry. 27: 920-931Karlsson I. Godderis J. Augusto De Mendonça Lima C. et al.

A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia.

Int J Geriatr Psychiatry. 15: 295-305de Vasconcelos Cunha U.G. Lopes Rocha F. Avila de Melo R. et al.

A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia.

Dement Geriatr Cogn Disord. 24: 36-41Oslin D.W. Ten Have T.R. Streim J.E. et al.

Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.

J Clin Psychiatry. 64: 875-882Cumbo E. Cumbo S. Torregrossa S. et al.

Treatment effects of vortioxetine on cognitive functions in mild Alzheimer’s disease patients with depressive symptoms: a 12 month, open-label, observational study.

J Prev Alzheimers Dis. 6: 192-197Bobo W.V. Grossardt B.R. Lapid M.I. et al.

Frequency and predictors of the potential overprescribing of antidepressants in elderly residents of a geographically defined U.S. population.

Pharmacol Res Perspect. 7: e00461

The relationship between anxiety and alzheimer’s disease.

J Alzheimers Dis Rep. 5: 171-177Porter V.R. Buxton W.G. Fairbanks L.A. et al.

Frequency and characteristics of anxiety among patients with Alzheimer’s disease and related dementias.

J Neuropsychiatry Clin Neurosci. 15: 180-186Dimitriou T.-D. Verykouki E. Papatriantafyllou J. et al.

Non-Pharmacological interventions for the anxiety in patients with dementia. A cross-over randomised controlled trial.

Behav Brain Res. 390: 112617van der Steen J.T. Smaling H.J. van der Wouden J.C. et al.

Music-based therapeutic interventions for people with dementia.

Cochrane Database Syst Rev. 7: CD003477Jin J.W. Nowakowski S. Taylor A. et al.

Cognitive behavioral therapy for mood and insomnia in persons with dementia: A systematic review.

Alzheimer Dis Assoc Disord. 35: 366-373Santa Cruz M.R. Hidalgo P.C. Lee M.S. et al.

Buspirone for the treatment of dementia with behavioral disturbance.

Int Psychogeriatr. 29: 859-862Marston L. Livingston G. Laybourne A. et al.

Becoming or remaining agitated: the course of agitation in people with dementia living in care homes. The english longitudinal managing agitation and raising quality of life (MARQUE) study.

J Alzheimers Dis. 76: 467-473Vik-Mo A.O. Giil L.M. Borda M.G. et al.

The individual course of neuropsychiatric symptoms in people with Alzheimer’s and Lewy body dementia: 12-year longitudinal cohort study.

Br J Psychiatry. 216: 43-48

Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: a systematic review and Bayesian network meta-analysis.

Int J Nurs Stud. 102: 103489Watt J.A. Goodarzi Z. Veroniki A.A. et al.

Comparative efficacy of interventions for aggressive and agitated behaviors in dementia: a systematic review and network meta-analysis.

Ann Intern Med. 171: 633-642Weintraub D. Drye L.T. Porsteinsson A.P. et al.

Time to response to citalopram treatment for agitation in Alzheimer disease.

Am J Geriatr Psychiatry. 23: 1127-1133Viscogliosi G. Chiriac I.M. Ettorre E.

Efficacy and safety of citalopram compared to atypical antipsychotics on agitation in nursing home residents with alzheimer dementia.

J Am Med Dir Assoc. 18: 799-802Newell J. Yesavage J.A. Taylor J.L. et al.

Sedation mediates part of Citalopram’s effect on agitation in Alzheimer’s disease.

J Psychiatr Res. 74: 17-21Banerjee S. High J. Stirling S. et al.

Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.

Lancet. 398: 1487-1497Frederiksen K.S. Cooper C. Frisoni G.B. et al.

A European Academy of Neurology guideline on medical management issues in dementia.

Eur J Neurol. 27: 1805-1820Aigbogun M.S. Cloutier M. Gauthier-Loiselle M. et al.

Real-world treatment patterns and characteristics among patients with agitation and dementia in the United States: findings from a large, observational, retrospective chart review.

J Alzheimers Dis. 77: 1181-1194Kongpakwattana K. Sawangjit R. Tawankanjanachot I. et al.

Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.

Br J Clin Pharmacol. 84: 1445-1456

Schedule of Pharmaceutical Benefits, General Pharmaceutical Schedule - Volume 1, published by: Australian Government, Department of Health. Canberra, Commonwealth of Australia.January 2022. Available at: https://www.pbs.gov.au/publication/schedule/2022/07/2022-07-01-general-%20schedule-volume-1.pdf.

Committee for Medicinal Products for Human Use (CHMP)

Opinion following an article 30 referral for risperdal and associated names.

European Medicines Agency, London

Risperidone - Restriction of the Dementia Indication - Recalls and safety alerts.

() ()Mintzer J.E. Tune L.E. Breder C.D. et al.

Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.

Am J Geriatr Psychiatry. 15: 918-931Devanand D.P. Crocco E. Forester B.P. et al.

Low dose lithium treatment of behavioral complications in Alzheimer’s disease: lit-AD randomized clinical trial.

Am J Geriatr Psychiatry. https://doi.org/10.1016/j.jagp.2021.04.014Stella F. Valiengo L.C.L. de Paula V.J.R. et al.

Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: systematic review.

Trends Psychiatry Psychother. https://doi.org/10.47626/2237-6089-2021-0288Ballard C.G. Coate B. Abler V. et al.

Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer’s disease psychosis: a post hoc analysis.

Int J Geriatr Psychiatry. 35: 1402-1408https://doi.org/10.1002/gps.5381Cummings J.L. Lyketsos C.G. Peskind E.R. et al.

Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial.

JAMA. 314: 1242-1254Watt J.A. Goodarzi Z. Veroniki A.A. et al.

Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis.

BMC Geriatr. 20: 212Tariot P.N. Erb R. Podgorski C.A. et al.

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.

Am J Psychiatry. 155: 54-61Liu K.Y. Borissova A. Mahmood J. et al.

Pharmacological treatment trials of agitation in Alzheimer’s disease: a systematic review of ClinicalTrials.gov registered trials.

Alzheimers Dement (N Y). 7: e12157

The incidence of dementia-related psychosis in people with dementia: Results from a survey of 302 U.S. healthcare providers.

Alzheimers Dement. 16https://doi.org/10.1002/alz.047138Vilalta-Franch J. López-Pousa S. Calvó-Perxas L. et al.

Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality.

Am J Geriatr Psychiatry. 21: 1135-1143Maust D.T. Kim H.M. Seyfried L.S. et al.

Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.

JAMA Psychiatry. 72: 438-445Yeh T.-C. Tzeng N.-S. Li J.-C. et al.

Mortality risk of atypical antipsychotics for behavioral and psychological symptoms of dementia: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials.

J Clin Psychopharmacol. 39: 472-478Ballard C. Hanney M.L. Theodoulou M. et al.

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.

Lancet Neurol. 8: 151-157

Five things physicians and patients should question.

American Psychiatric Association Choosing wisely, Philadelphia, PA

American Geriatrics Society | Choosing Wisely.

() ()

Evidence-based treatment and monitoring strategies for dementia-related psychosis.

J Clin Psychiatry. 82https://doi.org/10.4088/JCP.AD19038BR4CYunusa I. Rashid N. Abler V. et al.

Comparative efficacy, safety, tolerability, and effectiveness of antipsychotics in the treatment of dementia-related psychosis (DRP): a systematic literature review.

J Prev Alzheimers Dis. 8: 520-533Yunusa I. Alsumali A. Garba A.E. et al.

Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis.

JAMA Netw Open. 2: e190828Mühlbauer V. Möhler R. Dichter M.N. et al.

Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia.

Cochrane Database Syst Rev. 12: CD013304Ballard C. Banister C. Khan Z. et al.

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.

Lancet Neurol. 17: 213-222Tariot P.N. Cummings J.L. Soto-Martin M.E. et al.

Trial of Pimavanserin in Dementia-Related Psychosis.

N Engl J Med. 385: 309-319

Difficult choices in treating Parkinson’s disease psychosis.

Lancet Neurol. 17: 569Naasan G. Shdo S.M. Rodriguez E.M. et al.

Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms.

Brain. 144: 999-1012Badwal K. Kiliaki S.A. Dugani S.B. et al.

Psychosis management in lewy body dementia: A comprehensive clinical approach.

J Geriatr Psychiatry Neurol. 19https://doi.org/10.1177/0891988720988916

Treatment of psychosis in Parkinson’s disease and dementia with Lewy Bodies: a review.

Parkinsonism Relat Disord. 75: 55-62Taylor J.-P. McKeith I.G. Burn D.J. et al.

New evidence on the management of Lewy body dementia.

Lancet Neurol. 19: 157-169Borges L.G. Rademaker A.W. Bigio E.H. et al.

Apathy and disinhibition related to neuropathology in amnestic versus behavioral dementias.

Am J Alzheimers Dis Other Demen. 34: 337-343Magrath Guimet N. Miller B.L. Allegri R.F. et al.

What do we mean by behavioral disinhibition in frontotemporal dementia?.

Front Neurol. 12: 707799Keszycki R.M. Fisher D.W. Dong H.

The hyperactivity-impulsivity-irritiability-disinhibition-aggression-agitation domain in Alzheimer’s disease: current management and future directions.

Front Pharmacol. 10: 1109Sarangi A. Jones H. Bangash F. et al.

Treatment and management of sexual disinhibition in elderly patients with neurocognitive disorders.

Cureus. 13: e18463Liljegren M. Naasan G. Temlett J. et al.

Criminal behavior in frontotemporal dementia and Alzheimer disease.

JAMA Neurol. 72: 295-300Trieu C. Gossink F. Stek M.L. et al.

Effectiveness of pharmacological interventions for symptoms of behavioral variant frontotemporal dementia: a systematic review.

Cogn Behav Neurol. 33: 1-15Nisar M. Abubaker Z.J. Nizam M.A. et al.

Behavioral and cognitive response to selective serotonin reuptake inhibitors in frontotemporal lobar degeneration: a systematic review and meta-analysis.

Clin Neuropharmacol. 44: 175-183Hughes L.E. Rittman T. Regenthal R. et al.

Improving response inhibition systems in frontotemporal dementia with citalopram.

Brain. 138: 1961-1975Nagata T. Shinagawa S. Nakajima S. et al.

Classification of neuropsychiatric symptoms requiring antipsychotic treatment in patients with Alzheimer’s disease: analysis of the CATIE-AD study.

J Alzheimers Dis. 50: 839-845Lee K.S. Kim S.-H. Hwang H.-J.

Behavioral and Psychological symptoms of dementia and antipsychotic drug use in the elderly with dementia in korean long-term care facilities.

Drugs Real World Outcomes. 2: 363-368Nomoto H. Matsubara Y. Ichimiya Y. et al.

A case of frontotemporal dementia with sexual disinhibition controlled by aripiprazole.

Psychogeriatrics. 17: 509-510

Aripiprazole for the Treatment of inappropriate sexual behavior: case report of an Alzheimer’s disease patient known as heterosexual with recently shifted sexual orientation to same gender.

J Alzheimers Dis Rep. 2: 117-121Sherman C. Liu C.S. Herrmann N. et al.

Prevalence, neurobiology, and treatments for apathy in prodromal dementia.

Int Psychogeriatr. 30: 177-184Merrilees J. Dowling G.A. Hubbard E. et al.

Characterization of apathy in persons with frontotemporal dementia and the impact on family caregivers.

Alzheimer Dis Assoc Disord. 27: 62-67Mortby M.E. Adler L. Agüera-Ortiz L. et al.

Apathy as a treatment target in alzheimer’s disease: implications for clinical trials.

Am J Geriatr Psychiatry. https://doi.org/10.1016/j.jagp.2021.06.016Cai Y. Li L. Xu C. et al.

The effectiveness of non-pharmacological interventions on apathy in patients with dementia: a systematic review of systematic reviews.

Worldviews Evid Based Nurs. 17: 311-318Theleritis C. Siarkos K. Politis A.A. et al.

A systematic review of non-pharmacological treatments for apathy in dementia.

Int J Geriatr Psychiatry. 33: e177-e192Ruthirakuhan M.T. Herrmann N. Abraham E.H. et al.

Pharmacological interventions for apathy in Alzheimer’s disease.

Cochrane Database Syst Rev. 5: CD012197Mintzer J. Lanctôt K.L. Scherer R.W. et al.

Effect of methylphenidate on apathy in patients with alzheimer disease: the ADMET 2 randomized clinical trial.

JAMA Neurol. 78: 1324-1332Frakey L.L. Salloway S. Buelow M. et al.

A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer’s disease.

J Clin Psychiatry. 73: 796-801Takemoto M. Ohta Y. Hishikawa N. et al.

The efficacy of sertraline, escitalopram, and nicergoline in the treatment of depression and apathy in alzheimer’s disease: the okayama depression and apathy project (ODAP).

J Alzheimers Dis. 76: 769-772Zhou T. Wang J. Xin C. et al.

Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer’s disease: A clinical trial.

Exp Ther Med. 17: 1625-1630Padala P.R. Padala K.P. Majagi A.S. et al.

Selective serotonin reuptake inhibitors-associated apathy syndrome: A cross sectional study.

Medicine (Baltimore). 99: e21497Maier F. Spottke A. Bach J.-P. et al.

Bupropion for the treatment of apathy in alzheimer disease: a randomized clinical trial.

JAMA Netw Open. 3: e206027Gelderblom H. Wüstenberg T. McLean T. et al.

Bupropion for the treatment of apathy in Huntington’s disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.

PLoS One. 12: e0173872Insel P.S. Mohlenhoff B.S. Neylan T.C. et al.

Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults.

JAMA Netw Open. 4: e2117573https://doi.org/10.1001/jamanetworkopen.2021.17573J

留言 (0)

沒有登入
gif